Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Roche’s ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
ACTRIMS-ECTRIMS 2014 -- Day 3, morning
MS Research Roundup: November 21, 2014
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
Episode 50 with Dr. David Tabby on balance vests for MS
Autoimmunity's next top models.
CMSC ACTRIMS Cooperative Annual Meeting
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
CXCL12-induced monocyte-endothelial interactions promote lymphocyte transmigration across an in vitro blood-brain barrier.
Defining the clinical course of multiple sclerosis: The 2013 revisions.
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.
Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: a multicentre retrospective study on 361 patients
Episode 47 with Dr. Hans Lassmann on oxidative stress in MS
Nature Medicine Retracts MS Paper With Ghost Data by Former GSK Researcher
Low testosterone is associated with disability in men with multiple sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 4
ISN-APSN Biennial Meeting
Episode 36 with Dr. Jenny Ting on the inflammasome
Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.

Pages